GB Sciences has created a pipeline for the development of novel medicines that are complex mixtures of compounds derived from the Cannabis plant. GBS Global Biopharma, Inc., owned by GB Sciences, now has:
GBS Global Biopharma partners with universities and contract research organizations (CROs), who bring both expertise and infrastructure at a reasonable cost to our program.
Our end goal is not to take these novel formulations to market ourselves, but to be the perfect partner to those companies with greater resources and experience in the marketing and distribution of medications worldwide.
The GBS Global Biopharma Scientific Advisory Board provides oversight for product development within GBS Global Biopharma’s intellectual property portfolio.
GB Sciences has several advantages over both pharmaceutical companies and academic researchers when it comes to the discovery and validation of new drug formulations from cannabis-derived compounds.
GBS’ intellectual property portfolio currently contains four patents that are issued in the US with corresponding patents issued internationally. Seven nonprovisional patent applications and four provisional patent applications are pending in the US and twenty-nine patent applications have been filed internationally. These contain formulations to tackle neuropathic pain, neurodegenerative disorders and cardiovascular disease among others.
GBS Global is creating a pipeline for the development of novel medicines.
Our goal is to be the perfect partner to research universities and organizations.